Spotlight on Pulmonary/Respiratory Medicine

Credits: 0.50 CME
Gaining Control in Moderate to Severe Asthma: A GameOn! Challenge
Michael E. Wechsler, MD, MMSc
Vindico

Gaining Control in Moderate to Severe Asthma: A GameOn! Challenge

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 23, 2021
Expires: March 22, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by


Target Audience

The intended audience for the activity is allergists, immunologists, pulmonologists, and other health care professionals involved in the management of patients with asthma.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the latest advances in treatment that target specific asthma phenotypes.
  • Outline the features of uncontrolled or persistent asthma and strategies for treatment intensification.
  • Examine the latest evidence regarding new options for uncontrolled asthma and how these agents may fit into existing treatment algorithms.

Activity Description

An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Guidelines from the European Respiratory Society as well as the American Thoracic Society recommend phenotypic assessment and consideration of select add-on biologic therapy for severe, poorly controlled asthma. Biologic therapies that modulate immunoglobulin E, interleukin (IL)-4/13, and IL-5 signaling pathways offer important options for patients whose asthma is inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing moderate to severe asthma will better enable health care professionals to tailor an individualized, targeted treatment approach. This Game On! activity is an interactive quiz in which participants answer questions, then select the level of confidence in their answers to achieve the highest score among their peers. Through this gaming activity, faculty will highlight advances in treatment that target specific asthma phenotypes; outline features of poorly controlled asthma and strategies for treatment intensification; and review the latest evidence regarding options for uncontrolled asthma.

Activity Chair

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, Sentien, Teva
Speakers Bureau: AstraZeneca, GlaxoSmithKline, Sanofi
Contracted Research: AstraZeneca, Sanofi

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 23, 2021
Expires: March 22, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by


Target Audience

The intended audience for the activity is allergists, immunologists, pulmonologists, and other health care professionals involved in the management of patients with asthma.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the latest advances in treatment that target specific asthma phenotypes.
  • Outline the features of uncontrolled or persistent asthma and strategies for treatment intensification.
  • Examine the latest evidence regarding new options for uncontrolled asthma and how these agents may fit into existing treatment algorithms.

Activity Description

An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Guidelines from the European Respiratory Society as well as the American Thoracic Society recommend phenotypic assessment and consideration of select add-on biologic therapy for severe, poorly controlled asthma. Biologic therapies that modulate immunoglobulin E, interleukin (IL)-4/13, and IL-5 signaling pathways offer important options for patients whose asthma is inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing moderate to severe asthma will better enable health care professionals to tailor an individualized, targeted treatment approach. This Game On! activity is an interactive quiz in which participants answer questions, then select the level of confidence in their answers to achieve the highest score among their peers. Through this gaming activity, faculty will highlight advances in treatment that target specific asthma phenotypes; outline features of poorly controlled asthma and strategies for treatment intensification; and review the latest evidence regarding options for uncontrolled asthma.

Activity Chair

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, Sentien, Teva
Speakers Bureau: AstraZeneca, GlaxoSmithKline, Sanofi
Contracted Research: AstraZeneca, Sanofi

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pulmonary/Respiratory Medicine Presentations

0.25 CME
Global Education Group
Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 3: A Case-Based Look at Managing Moderate-to-Severe Asthma

Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 3: A Case-Based Look at Managing Moderate-to-Severe Asthma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 13, 2021
Expires: July 13, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma
  • Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 13, 2021
Expires: July 13, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma
  • Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1.00 CME / MOC / CC
Vindico
Multidisciplinary Perspective in Chronic Cough: Streamlining Care for Your Patients

Multidisciplinary Perspective in Chronic Cough: Streamlining Care for Your Patients

Start

Activity Details

Free CME/MOC/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC
1.0 ABOHNS Continuing Certification
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
  • Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
  • 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC
1.0 ABOHNS Continuing Certification
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
  • Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
  • 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Frontline Checkpoint Inhibitor Monotherapy in NSCLC

Frontline Checkpoint Inhibitor Monotherapy in NSCLC

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Evaluate the survival advantage versus chemotherapy for current and emerging frontline checkpoint inhibitor monotherapies in advanced nondriver non-small cell lung cancer (NSCLC) with high PD-L1 expression

Activity Description

This learner-friendly 15-minute infographic activity is augmented by physician videos in an interactive approach to key safety and efficacy data for frontline pembrolizumab, atezolizumab, and cemiplimab monotherapies in advanced NSCLC.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Evaluate the survival advantage versus chemotherapy for current and emerging frontline checkpoint inhibitor monotherapies in advanced nondriver non-small cell lung cancer (NSCLC) with high PD-L1 expression

Activity Description

This learner-friendly 15-minute infographic activity is augmented by physician videos in an interactive approach to key safety and efficacy data for frontline pembrolizumab, atezolizumab, and cemiplimab monotherapies in advanced NSCLC.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

0.25 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Understanding Checkpoint Inhibitors in NSCLC

Understanding Checkpoint Inhibitors in NSCLC

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

0.25 CME
Global Education Group
Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 1: Evaluating Patients With Moderate-to-Severe Asthma

Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 1: Evaluating Patients With Moderate-to-Severe Asthma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 18, 2021
Expires: June 18, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC., Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 18, 2021
Expires: June 18, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC., Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME
Global Education Group
Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 2: Biologics for Moderate-to-Severe Asthma

Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 2: Biologics for Moderate-to-Severe Asthma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 11, 2021
Expires: June 11, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma

Faculty

Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 11, 2021
Expires: June 11, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma

Faculty

Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1.00 AAPA / CME / CPE
Vindico
Non-tuberculous Mycobacterial Lung Disease (NTM-LD): New Guidelines to Manage a Challenging Respiratory Disease

Non-tuberculous Mycobacterial Lung Disease (NTM-LD): New Guidelines to Manage a Challenging Respiratory Disease

Start

Activity Details

Free CME/CPE/AAPA
1.0 AMA PRA Category 1 Credit(s)
1.0 ACPE Contact Hour(s)
1.0 AAPA Category 1 CME Credits
Released: May 31, 2021
Expires: May 30, 2022
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with non-tuberculous mycobacterial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Identify patients with non-tuberculous mycobacterial lung disease (NTM-LD) using knowledge of pathophysiology, environmental factors, underlying conditions (eg, bronchiectasis), and risk factors.
  • Review the newly updated guideline recommendations for the diagnosis and treatment of NTM-LD.
  • Examine the strategies to manage adverse effects associated with treatment of NTM-LD including approaches to improve treatment adherence.

Activity Description

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. A range of clinical manifestations can arise from NTM infection. Pulmonary disease is the most common of these manifestations, often occurring in patients with underlying lung diseases, such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults, with the potential for chronic infection requiring long-term treatment and the potential for significant side effects. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and provide care informed by the latest clinical evidence and updated practice guidelines. In this educational activity, faculty will review pathophysiology of and risk factors for NTM, evidence-based guidelines for diagnosis and treatment, and strategies for managing adverse effects associated with NTM treatment regimens.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 1.0 contact hour of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-009-H01-P, effective 05/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

Accreditation Council for Pharmacy EducationThis activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1AAPA Category 1 CME credits. Approval is valid from 5/31/2021 to 5/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202737.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed Incorporated.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE/AAPA
1.0 AMA PRA Category 1 Credit(s)
1.0 ACPE Contact Hour(s)
1.0 AAPA Category 1 CME Credits
Released: May 31, 2021
Expires: May 30, 2022
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with non-tuberculous mycobacterial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Identify patients with non-tuberculous mycobacterial lung disease (NTM-LD) using knowledge of pathophysiology, environmental factors, underlying conditions (eg, bronchiectasis), and risk factors.
  • Review the newly updated guideline recommendations for the diagnosis and treatment of NTM-LD.
  • Examine the strategies to manage adverse effects associated with treatment of NTM-LD including approaches to improve treatment adherence.

Activity Description

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. A range of clinical manifestations can arise from NTM infection. Pulmonary disease is the most common of these manifestations, often occurring in patients with underlying lung diseases, such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults, with the potential for chronic infection requiring long-term treatment and the potential for significant side effects. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and provide care informed by the latest clinical evidence and updated practice guidelines. In this educational activity, faculty will review pathophysiology of and risk factors for NTM, evidence-based guidelines for diagnosis and treatment, and strategies for managing adverse effects associated with NTM treatment regimens.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 1.0 contact hour of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-009-H01-P, effective 05/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

Accreditation Council for Pharmacy EducationThis activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1AAPA Category 1 CME credits. Approval is valid from 5/31/2021 to 5/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202737.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed Incorporated.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME / MOC
Global Education Group
The HER Family: A Pan Tumor Approach

The HER Family: A Pan Tumor Approach

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: May 12, 2021
Expires: May 11, 2022
60 minutes to complete

Accredited By

This activity is provided by Global Education Group. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Learning Objectives

Upon completion of this activity, the clinician should be able to:

  • Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer 
  • Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC) 
  • Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease 

Activity Description

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

Statement of Educational Need

Clinical research seeks to expand the treatment armamentarium for solid tumors by investigating new or emerging HER2-targeted therapies in breast, lung, and gastric cancer; targeting HER3 and other escape mechanisms are also of interest. Given the rapidly evolving landscape of HER2-targeted therapies and the emerging role of HER3, clinicians require clear knowledge of the latest advances in order to deliver optimal cancer care.

Faculty

Sara M. Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA


Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL


Liza C. Villaruz, MD
Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA 

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sara M. Tolaney, MD, MPH
Consultant: AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, G1 Therapeutics, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceutics, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Samsung Bioepsis, Sanofi, SeaGen.
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, SeaGen.
 
Daniel Catenacci, MD
Consultant: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Honoraria: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Speaker’s Bureau: Daiichi Sankyo, Eli Lilly, Genentech/Roche, Guardant Health, Merck, Tempus.  

Liza C. Villaruz, MD, has nothing to disclose.  

The planners and managers have the following relevant financial relationships with ineligible companies:
  
Lindsay Borvansky has nothing to disclose. 
Andrea Funk has nothing to disclose. 
Liddy Knight has nothing to disclose. 
Ashley Cann has nothing to disclose. 
Agnes Yang has nothing to disclose. 
Sharon Powell has nothing to disclose. 
Elizabeth Johnson has nothing to disclose.  

Accreditation Statement

Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on May 12, 2021 and is valid for one year. Requests for credit must be made no later than May 11, 2022.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.     

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: May 12, 2021
Expires: May 11, 2022
60 minutes to complete

Accredited By

This activity is provided by Global Education Group. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Learning Objectives

Upon completion of this activity, the clinician should be able to:

  • Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer 
  • Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC) 
  • Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease 

Activity Description

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

Statement of Educational Need

Clinical research seeks to expand the treatment armamentarium for solid tumors by investigating new or emerging HER2-targeted therapies in breast, lung, and gastric cancer; targeting HER3 and other escape mechanisms are also of interest. Given the rapidly evolving landscape of HER2-targeted therapies and the emerging role of HER3, clinicians require clear knowledge of the latest advances in order to deliver optimal cancer care.

Faculty

Sara M. Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA


Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL


Liza C. Villaruz, MD
Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA 

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sara M. Tolaney, MD, MPH
Consultant: AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, G1 Therapeutics, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceutics, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Samsung Bioepsis, Sanofi, SeaGen.
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, SeaGen.
 
Daniel Catenacci, MD
Consultant: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Honoraria: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Speaker’s Bureau: Daiichi Sankyo, Eli Lilly, Genentech/Roche, Guardant Health, Merck, Tempus.  

Liza C. Villaruz, MD, has nothing to disclose.  

The planners and managers have the following relevant financial relationships with ineligible companies:
  
Lindsay Borvansky has nothing to disclose. 
Andrea Funk has nothing to disclose. 
Liddy Knight has nothing to disclose. 
Ashley Cann has nothing to disclose. 
Agnes Yang has nothing to disclose. 
Sharon Powell has nothing to disclose. 
Elizabeth Johnson has nothing to disclose.  

Accreditation Statement

Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on May 12, 2021 and is valid for one year. Requests for credit must be made no later than May 11, 2022.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.     

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. 

1.00 CME
SHM (Society of Hospital Medicine)
Hospitalists Guide to COVID-19

Hospitalists Guide to COVID-19

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

1.25 AANP / CME
AKH Inc., Advancing Knowledge in Healthcare
PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care

PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care

Start

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: April 12, 2021
Expires: April 12, 2022
75 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

  • Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  • Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
  • Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.

Activity Description

The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.

To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.

Agenda

  1. Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
  2. Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
  3. Personalized Patient Cases
  4. Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time

Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington


Alvin F. Wells, MD, PhD, FACR
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
  • Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Faculty (Presenter): Phillip Mease, MD, MACR

  • Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi

Faculty (Planner): Richard Martin, MD, MA

  • Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly

Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP

  • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designated this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
AANPThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: April 12, 2021
Expires: April 12, 2022
75 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

  • Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  • Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
  • Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.

Activity Description

The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.

To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.

Agenda

  1. Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
  2. Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
  3. Personalized Patient Cases
  4. Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time

Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington


Alvin F. Wells, MD, PhD, FACR
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
  • Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Faculty (Presenter): Phillip Mease, MD, MACR

  • Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi

Faculty (Planner): Richard Martin, MD, MA

  • Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly

Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP

  • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designated this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
AANPThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Pages